HS dosing

For adult and pediatric patients ≥12 years with moderate to severe hidradenitis suppurativa (HS)¹

Flexible maintenance dosing^1*

For adult patients¹

Start: Initial dose is 300 mg once weekly for five weeks. Stay: Maintenance dosing is 1 injection of 300 mg once every four weeks. For patients who don't adequately respond, you have a Q2W dosing option. Before a treatment switch, consider Q2W.

Just one UnoReady^® Pen per dose

_^.

Get your patients started with the UnoReady Pen

Suggested prescribing approach¹

COSENTYX (300 mg) once a week, 4 boxes, 4-week supply, 0 refills.

1 prescription for
loading dose
(Weeks 0, 1, 2, and 3)

COSENTYX (300 mg) Q4 weeks (1 box) or Q2 weeks (2 boxes), 11 refills.

1 prescription for maintenance dose

Covers Week 4 loading dose as well as maintenance dose.

If a patient does not adequately respond, consider increasing the dosage to 300 mg every 2 weeks.

For pediatric patients ≥12 years of age^1†

Weight-based dosage is administered by subcutaneous injection at Weeks 0, 1, 2, 3 and 4 and every 4 weeks thereafter.

For patients ≥30 kg and <90 kg, the recommended dose is 150 mg
For patients ≥90 kg, the recommended dose is 300 mg

ICD-10-CM code: L73.2

See devices >Explore patient resources >

*Adult patients may self-administer COSENTYX or be injected by a caregiver after proper training in subcutaneous injection technique using the UnoReady Pen.¹
^†Inform patients and caregivers that pediatric patients should not self-administer COSENTYX.

Definitions and reference

Definitions

ICD-10-CM, International Classification of Diseases, Tenth Revision, Clinical Modification; Q2, every 2; Q4, every 4.

Reference

1. Cosentyx. Prescribing information. Novartis Pharmaceuticals Corp.